Given that molecular heterogeneity may underlie differences in prognosis and responsivity to clinical therapy, we linked risk score to some GBM molecular features, such as TCGA Verhaak’s GBM classification, IDH mutation, and MGMT promoter methylation, and we confirmed that these samples are highly variable from patient to patient at a molecular level. The gene discussed is MGMT; the disease is glioblastoma.